PAFAH1B3 Antibody (monoclonal) (M02)
Mouse monoclonal antibody raised against a full length recombinant PAFAH1B3.
|Application ||WB, IF, E|
|Calculated MW||25734 Da|
|Other Names||Platelet-activating factor acetylhydrolase IB subunit gamma, PAF acetylhydrolase 29 kDa subunit, PAF-AH 29 kDa subunit, PAF-AH subunit gamma, PAFAH subunit gamma, PAFAH1B3, PAFAHG|
|Target/Specificity||PAFAH1B3 (AAH03016, 1 a.a. ~ 231 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||PAFAH1B3 Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes an acetylhydrolase that catalyzes the removal of an acetyl group from the glycerol backbone of platelet-activating factor. The encoded enzyme is a subunit of the platelet-activating factor acetylhydrolase isoform 1B complex, which consists of the catalytic beta and gamma subunits and the regulatory alpha subunit. This complex functions in brain development. A translocation between this gene on chromosome 19 and the CDC-like kinase 2 gene on chromosome 1 has been observed, and was associated with mental retardation, ataxia, and atrophy of the brain. Alternatively spliced transcript variants have been described.
1.Loss of PAFAH1B2 Reduces Amyloid-?] Generation by Promoting the Degradation of Amyloid Precursor Protein C-Terminal Fragments.Page RM, Munch A, Horn T, Kuhn PH, Colombo A, Reiner O, Boutros M, Steiner H, Lichtenthaler SF, Haass C.J Neurosci. 2012 Dec 12;32(50):18204-18214.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.